Embecta (EMBC) Stock Price, News & Analysis

Company Overview

Embecta is a medical device company focused on products for people who use insulin to manage diabetes. Its portfolio includes pen needles, insulin syringes and safety injection devices, serving both individuals and healthcare professionals.

The company was formed in 2022 when Becton, Dickinson and Company (BD) separated its diabetes care business into an independent company. Embecta continues to build on that business’s history of developing injection devices for diabetes care.

Embecta serves customers in markets around the world. Its products are designed to support insulin delivery and help meet the needs of people with diabetes across a range of care settings.

Key Stats

• Today's Range: $6.16 to $6.50
• 50-Day Range: $4.89 to $6.86
• 52-Week Range: $2.77 to $14.81
• Volume: 566,841 shs
• Average Volume: 819,271 shs
• Market Capitalization: $366.02 million
• P/E Ratio: 4.36
• Dividend Yield: 0.62%
• Price Target: $11.00
• Consensus Rating: Reduce

Embecta Stock Analysis - MarketRank™

Embecta scored higher than 65% of companies evaluated by MarketBeat, and ranked 306th out of 892 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.1 / 5
• Analyst Rating: Reduce

Consensus Rating

Embecta has received a consensus rating of Reduce. The company's average rating score is 1.80, and is based on no strong buy ratings, no buy ratings, 4 hold ratings, and 1 sell rating.

Upside Potential

Embecta has a consensus price target of $11.00, representing about 70.3% upside from its current price of $6.46.

Amount of Analyst Coverage

Embecta has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: -4.35%

Earnings Growth

Earnings for Embecta are expected to decrease by -4.35% in the coming year, from $1.84 to $1.76 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Embecta is 4.36, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.41.

Price to Earnings Ratio vs. Sector

The P/E ratio of Embecta is 4.36, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.71.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

10.40% of the float of Embecta has been sold short.

Short Interest Ratio / Days to Cover

Embecta has a short interest ratio ("days to cover") of 6.83.

Change versus previous month

Short interest in Embecta has recently decreased by 0.93%, indicating that investor sentiment is improving.

Dividend

• Score: 1.7 / 5
• Dividend Strength: Weak

Dividend Yield

Embecta has a dividend yield of 0.62%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Embecta does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Embecta is 2.70%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Embecta will have a dividend payout ratio of 2.27% next year. This indicates that Embecta will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 1.03

News Sentiment

Embecta has a news sentiment score of 1.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Embecta this week, compared to 8 articles on an average week.

MarketBeat Follows

1 people have added Embecta to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.5 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Embecta insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $37,003.00 in company stock.

Percentage Held by Insiders

1.30% of the stock of Embecta is held by insiders.

Percentage Held by Institutions

93.83% of the stock of Embecta is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/07/2026
• Record date for 9/15 Dividend: 8/27/2026
• Ex-Dividend for 9/15 Dividend: 8/27/2026
• Dividend Payable: 9/15/2026
• Today: 11/14/2026
• Next Earnings (Estimated): 11/24/2026
• Fiscal Year End: 9/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: Healthcare Supplies
• Current Symbol: NASDAQ:EMBC
• CIK: 1872789
• Web: www.embecta.com
• Phone: 201-847-6880
• Fax: N/A
• Employees: 1,850
• Year Founded: 2022

Price Target and Rating

• Average Price Target for Embecta: $11.00
• High Price Target: $25.00
• Low Price Target: $3.00
• Potential Upside/Downside: +70.3%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.80
• Research Coverage: 5 Analysts

Profitability

• EPS (Trailing Twelve Months): $1.48
• Trailing P/E Ratio: 4.36
• Forward P/E Ratio: 3.67
• P/E Growth: N/A
• Net Income: $95.40 million
• Net Margins: 8.59%
• Pretax Margin: 12.27%
• Return on Equity: -19.25%
• Return on Assets: 10.82%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.68
• Quick Ratio: 1.17

Sales & Book Value

• Annual Sales: $1.08 billion
• Price / Sales: 0.34
• Cash Flow: $4.01 per share
• Price / Cash Flow: 1.61
• Book Value: ($11.12) per share
• Price / Book: -0.58

Miscellaneous

• Outstanding Shares: 56,660,000
• Free Float: 55,923,000
• Market Cap: $366.02 million
• Optionable: Optionable
• Beta: 0.81